Bonus Biogroup Stock Gross Profit
| BBIXF Stock | USD 0.02 0.00 0.00% |
Bonus BioGroup fundamentals help investors to digest information that contributes to Bonus BioGroup's financial success or failures. It also enables traders to predict the movement of Bonus Pink Sheet. The fundamental analysis module provides a way to measure Bonus BioGroup's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Bonus BioGroup pink sheet.
Bonus |
Bonus BioGroup Company Gross Profit Analysis
Bonus BioGroup's Gross Profit is the most basic measure of business operational efficiency. It is simply the difference between sales revenue and the cost associated with making a product or providing a service. It is calculated before deducting administrative expenses, taxes, and interest payments.
Gross Profit varies significantly from one sector to another and tells an investor how much money a business would have made if it didn't have to pay any overhead expenses such as salary, taxes, or rent.
| Competition |
According to the company disclosure, Bonus BioGroup reported 0.0 of gross profit. This is 100.0% lower than that of the Healthcare sector and 100.0% lower than that of the Biotechnology industry. The gross profit for all United States stocks is 100.0% higher than that of the company.
Bonus Gross Profit Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Bonus BioGroup's direct or indirect competition against its Gross Profit to detect undervalued stocks with similar characteristics or determine the pink sheets which would be a good addition to a portfolio. Peer analysis of Bonus BioGroup could also be used in its relative valuation, which is a method of valuing Bonus BioGroup by comparing valuation metrics of similar companies.Bonus BioGroup is currently under evaluation in gross profit category among its peers.
Bonus Fundamentals
| Return On Equity | -0.55 | |||
| Return On Asset | -0.0636 | |||
| Current Valuation | 48.99 M | |||
| Shares Outstanding | 1.17 B | |||
| Shares Owned By Insiders | 49.72 % | |||
| Shares Owned By Institutions | 0.09 % | |||
| Price To Book | 4.05 X | |||
| EBITDA | (88.03 M) | |||
| Net Income | (90.08 M) | |||
| Debt To Equity | 0.15 % | |||
| Current Ratio | 9.13 X | |||
| Cash Flow From Operations | (39.84 M) | |||
| Beta | 1.4 | |||
| Market Capitalization | 62.59 M | |||
| Total Asset | 104.32 M | |||
| Net Asset | 104.32 M |
About Bonus BioGroup Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Bonus BioGroup's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Bonus BioGroup using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Bonus BioGroup based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Currently Active Assets on Macroaxis
Other Information on Investing in Bonus Pink Sheet
Bonus BioGroup financial ratios help investors to determine whether Bonus Pink Sheet is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Bonus with respect to the benefits of owning Bonus BioGroup security.